Back to Search

APRE

Aprea Therapeutics, Inc. Common stock
Data: 2026-01-30
$0.796
Price
33.78%
Change
$4.65
52W High
$0.548
52W Low
Buy/Sell Forecast Trendline Why Moving Charts Options

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Quick Stats
Jan 30, 2026

49.4

AI Score

HOLD

439.59

Volume Ratio

Next Earnings

14

+ve Days (30d)

15

-ve Days (30d)

APRE Stock Summary

Last updated Jan 30, 2026

APRE is currently trading at $0.796, positioned below its 200-day moving average of $1.45, suggesting bearish momentum. The stock has a 52-week range of $0.548 to $4.65.

Technical Analysis: The 50-day moving average stands at $0.96, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 43.493, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.576, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates APRE at 49.4/100 with a HOLD recommendation.

APRE (Aprea Therapeutics, Inc. Common stock) Indicators

Last updated Jan 30, 2026

Indicator Value
RSI(14) 43.493
CMF (20) -0.576
ROC (10) -10.962
ADX (14) 20.47
Indicator Value
MACD (12,26,9) -0.063
AROONOSC (14) 7.143
WILLAMS %R (14) -73.673
MFI (14) 96.235
APRE Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

APRE Price vs Max Options Open Interest
APRE Max Change In Options Open Interest

APRE Options - Sort by Max open Interest (near term)

31st January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

APRE Daily Out of Money Options - Sort by Max open Interest (near term)

31st January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

APRE Daily In the Money Options - Sort by Max open Interest (near term)

31st January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

APRE Most Active Options by Volume(near term)

31st January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI		 Ask PC Delta Vega Volatility % change Track

Aprea Therapeutics, Inc. Common stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.

APRE Moving Averages Analysis

APRE (Aprea Therapeutics, Inc. Common stock) Simple Moving Averages

Moving Averages are last updated Jan 30, 2026

Days MA
10 0.81
20 0.86
30 0.88
50 0.96
100 1.2
200 1.45

APRE Fundamental Analysis

P/E (Forward) 0
P/E (Trailing) --
Market Cap ($) 5.3 million
Earnings/Share ($) -2.12
Net Proft Margin (%) 0
Dividend/Share ($) --
EPS Estimate Current Year ($) -1.96
EPS Estimate Next Year ($) -0.86
WallStreet Target Price ($) 7
Most Recent Quarter